The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV

Affiliations

¹ UTHealth Houston, Houston, Texas.
² Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ School of Engineering Medicine, Texas A&M University, Houston, Texas, and ForeSpect PLLC, Pearland, Texas.
⁴ Weill Cornell College of Medicine, New York, New York.
⁵ Social & Scientific Systems, Inc., and FHI 360, Durham, North Carolina.
⁶ National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
⁷ University of Cincinnati, Cincinnati, Ohio.
⁸ University of Alabama at Birmingham, Birmingham, Alabama.
⁹ Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Rio de Janeiro, Brazil.
¹⁰ Massachusetts General Hospital, Boston, Massachusetts.
¹¹ Johns Hopkins University, Baltimore, Maryland.
¹² Rush University, Chicago, Illinois.
¹³ University of Southern California, Los Angeles, California.
¹⁴ University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Jordan E Lake et al. Ann Intern Med. 2024 Jun.

. 2024 Jun;177(6):835-838.

doi: 10.7326/M23-3354. Epub 2024 Apr 30.

¹ UTHealth Houston, Houston, Texas.
² Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
³ School of Engineering Medicine, Texas A&M University, Houston, Texas, and ForeSpect PLLC, Pearland, Texas.
⁴ Weill Cornell College of Medicine, New York, New York.
⁵ Social & Scientific Systems, Inc., and FHI 360, Durham, North Carolina.
⁶ National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
⁷ University of Cincinnati, Cincinnati, Ohio.
⁸ University of Alabama at Birmingham, Birmingham, Alabama.
⁹ Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Rio de Janeiro, Brazil.
¹⁰ Massachusetts General Hospital, Boston, Massachusetts.
¹¹ Johns Hopkins University, Baltimore, Maryland.
¹² Rush University, Chicago, Illinois.
¹³ University of Southern California, Los Angeles, California.
¹⁴ University of Colorado Anschutz Medical Campus, Aurora, Colorado.

No abstract available

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M23-3354.

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. Epub 20160915. doi: 10.1056/NEJMoa1607141. - DOI - PubMed
1. Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113–24. Epub 20201113. doi: 10.1056/NEJMoa2028395. - DOI - PubMed
1. Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Alimentary pharmacology & therapeutics. 2021;54(9):1150–61. Epub 20210927. doi: 10.1111/apt.16608. - DOI - PMC - PubMed
1. Bonora E, Formentini G, Calcaterra F, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care. 2002;25(7):1135–41. doi: 10.2337/diacare.25.7.1135. - DOI - PubMed
1. Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140(16):1308–17. Epub 20190918. doi: 10.1161/circulationaha.119.041998. - DOI - PMC - PubMed